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Ventricular tachyarrhythmias due to a “treatable” or “revers-
ible” cause (like those due to an acute myocardial infarction
[MI], electrolyte imbalance or drugs) are considered a “class
III indication” for cardioverter defibrillator (ICD) implan-
tation (1). In other words, ICD implantation is regarded as
unnecessary (at best) or explicitly contraindicated for pa-
tients with ventricular tachycardia/fibrillation (VT/VF) due
to a “curable cause.” This is based on the premise that
patients with VT/VF due to a treatable cause have a low risk
of death from recurrent arrhythmias if the specific cause is
treated. In this issue of the Journal, Wyse et al. (2) present
data suggesting that patients with VT/VF due to treatable
(and treated) causes may not have a good prognosis after all.
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In this study (2), 2,000 patients with “primary” VT/VF
(from the Antiarrhythmics Versus Implantable Defibrilla-
tors [AVID] Study) (3) were compared to 278 patients with
VT/VF that was “secondary” to a treatable cause. The last
group consisted of patients who entered the AVID Registry
by virtue of having sustained VT/VF, but were excluded
from the AVID Study because the arrhythmia was attrib-
uted to an ischemic event, an electrolyte imbalance or a
proarrhythmic drug. The 2,013 patients with “primary
VT/VF” were treated according to the AVID-Study ran-
domization (3) with either an ICD (52% of patients) or a
class III antiarrhythmic (mostly amiodarone). In contrast,
the treatment of patients with “correctable causes” for
VT/VF included correction of the identified etiology, such
as revascularization for “ischemic VF” or discontinuation of
proarrhythmic drug therapy. Thus, only 20% of patients
with “treatable VT/VF” had ICD implantation.
The mortality of patients with “treatable” VT/VF was
unexpectedly high (27% at three years) and similar to that of
patients with VT/VF for whom a curable cause could not be
identified (24% at three years) (2). Among patients not
treated with ICDs, mortality was 15% at one year and 29%
at three years when a “treatable cause” was identified (and
treated) versus 14% at one year and 30% at three years when
such cause could not be identified (A.P. Hallstrom, personal
communication, 2001).
Although AVID was a randomized trial (3), the report by
Wyse et al. (2) is based in part on the AVID Registry. Since
assignment to the “primary” or “treatable” VT/VF groups
was not randomized, it is possible that some confounding
factors affected the mortality of the last group and made it
look as bad as that of patients with primary VT/VF. For
example, data on the timing and mode of death are not
available for patients in the Registry (those with “treatable”
causes). Thus, one cannot exclude the possibility that many
patients with “treatable” VT/VF died from complications of
the index arrhythmic insult rather than from recurrent
arrhythmias. This is unlikely, however, because all patients
had to be fully conscious and in hemodynamically stable
condition before entering the Registry. This suggests that
the mortality figures recorded essentially reflect long-term
mortality. Moreover, patients with “treatable” arrhythmias
had (as a group) several characteristics associated with
improved prognosis: they were younger, had better left
ventricular ejection fraction (EF) and received beta-
adrenergic blocking agents or revascularization more com-
monly than patients with arrhythmias not considered “treat-
able.” Accordingly, patients with treatable arrhythmias
should have done better. In fact, after correcting for these
variables, patients with treatable arrhythmias appeared to do
worse than patients with primary arrhythmias (2). How can
one explain the adverse prognosis of patients with VT/VF
due to treatable causes?
One explanation is that the “treatable causes” of VT/VF
are not really treatable. In the study by Wyse et al. (2), the
correctable cause for VT/VF most commonly identified was
ischemia. Ischemic VT/VF was diagnosed in two of three
cases with “secondary VT/VF” and was ascribed to a new
Q-wave MI in 42% of these cases, to a “non–Q-wave” MI
in 45% and to acute ischemia without infarction in the
remaining 12%. Large prospective trials suggest that pa-
tients presenting with acute MI, who develop VF shortly
thereafter, have an excellent long-term prognosis (4). How-
ever, data on the prognosis of patients presenting with VF,
in whom an acute MI is subsequently diagnosed, are more
limited. Schaffer and Cobb (5) first suggested that the
long-term risk for recurrent VF is reduced when the
arrhythmia is related to an acute MI. In that study, only 5%
of patients with “VF due to MI”—but 33% of those with
VF not occurring in the setting of acute MI—had recurrent
VF at four years. It should be noted, however, that such
divergence applied only when the diagnosis of MI was based
on the appearance of new pathologic Q waves. When the
diagnosis of “acute MI” was based only on cardiac enzyme
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levels, the risk for recurrent VF was actually 18% (5).
Goldstein et al. (6) showed similar results: among 142
patients with out-of-hospital VF due to coronary artery
disease, the one-year mortality was “high” (29%) when no
MI could be identified, low (11%) when the arrhythmia was
related to an MI defined as a new Q-wave infarction and
“intermediate” (20%) when the MI diagnosis was based on
cardiac isoenzymes (6). This “intermediate risk” probably
reflects the fact that patients with enzyme elevations—but
no Q-wave formation—after resuscitation, probably repre-
sent a heterogeneous group that includes patients with true
non-Q-wave infarction as well as patients whose enzyme
elevation is due to the arrhythmia or the resuscitation (see
below). Finally, the assumption that patients who developed
VF during acute ischemia—without infarction—will remain
free of arrhythmias if the ischemia is treated is a logical
presumption that has little scientific support. Ischemia may
recur (because of incomplete revascularization or disease
progression) and uncertainty remains as to the risk for
recurrent VF among patients who had “ischemic VF” and
developed recurrent ischemia. Interestingly, one animal
model of ischemic VF (involving coronary artery occlusion
during exercise) suggests that some “inborn predisposition”
to ischemic VF may actually exist (7). Similar arguments can
be offered against the infallible prevention of VT/VF
recurrence when the original insult is a proarrhythmic drug.
The list of drugs that cause QT prolongation and torsades
de pointes keeps expanding and patients who developed
torsades when treated with one drug are prone to develop
the same arrhythmia if treated with a second proarrhythmic
drug. Furthermore, patients who had torsades de pointes
during atrioventricular block may later develop torsades
(despite a normally functioning pacemaker) if challenged
with medications that prolong repolarization (8), probably
reflecting an inborn repolarization abnormality (9).
A different explanation for the findings by Wyse et al. (2)
may be that the identified “treatable causes” of VT/VF were
not really the “cause” the arrhythmias. The criteria for
defining a “reversible” cause for arrhythmia were rather
vague (2). The most common reason for attributing a
“reversible” category to an arrhythmia was the suspicion that
the arrhythmia was due to an “ischemic event.” This implies
that some ST changes or a rise in cardiac enzyme levels were
seen after resuscitation. However, the magnitude of these
changes was not specified. This study limitation is impor-
tant because ST-segment elevation and enzymes rise could
be due to the arrhythmias or the DC shocks. Transient
ST-segment elevation (10), QRS widening (11) and en-
zymes rise have been documented after elective DC cardio-
version of atrial arrhythmias and it is conceivable that more
severe abnormalities follow repeated DC shocks during
prolonged VF. Indeed, reversible left ventricular dysfunc-
tion may result from prolonged resuscitations (12). Thus,
one case of VF diagnosed as “due to non–Q-wave infarc-
tion” might be, in fact, a case of primary VF with secondary
ST-changes, enzymes rise and left ventricular dysfunction.
Furthermore, since the induction of monomorphic VT with
programmed ventricular stimulation demonstrates persis-
tence of an arrhythmic substrate, many clinicians would
require a negative electrophysiologic study before conclud-
ing that the cardiac arrest was solely due to ischemia. Yet,
this was not mandatory in the present study. Consequently,
we do not know if the patients with VT/VF “due to
reversible ischemia” had a bad prognosis because the “re-
versible ischemia” was not truly “reversible” or because the
arrhythmia was not due to ischemia to begin with. The same
argument holds true for “electrolyte imbalance.” Physicians
in AVID had the discretion to define when the arrhythmia
was “caused by hypokalemia.” Hypokalemia increases the
risk for VF during MI (4) and facilitates drug-induced
torsades de pointes (13). However, it is difficult to find
reports in which hypokalemia was the sole cause of VT/VF.
Yet, “electrolyte imbalance” (presumably hypokalemia) was
the “cause of VT/VF” in 10% of “treatable cases” in this
study (2). Of note, mild hypokalemia can be the result,
rather than the cause, of VT/VF (14).
Patients with “treatable arrhythmias” were treated ac-
cording to the physicians’ judgment and 20% of them
received an ICD. This implies that in many cases, the
enrolling physicians were not convinced that the identified
“reversible” cause for VT/VF was truly reversible or was
truly the cause. There is one explanation for this paradox:
one thing is to disqualify patients from entering a random-
ized trial whenever an exclusion criterion (in this case a
“potentially curable cause” for VT/VF) is recognized. A
different thing is to treat such patient based on that
criterion. Discovery of “hypokalemia” after resuscitation
could lead to the conscientious physician against enrollment
of a patient to the AVID trial simply to avoid biasing the
results of this important study, even if he/she was not
convinced that hypokalemia had much to do with the
arrhythmia. Yet, such a patient would appear in the authors’
database as one with “VF due to electrolyte imbalance.”
Wyse et al. (2) should be congratulated for challenging
the dogma that treatment of the cause for VT/VF will
consistently result in a good prognosis. The authors did not
conclude that indiscriminate ICD implantation is the solu-
tion for all patients with VT/VF and neither should the
reader. Their study has no data on the mode of death and
we do not know if patients with “treated causes” of VT/VF
died from recurrent arrhythmias. However, one should
recognize that our ability to identify VT/VF survivors who
are at low risk for recurrence (even with the aid of
electrophysiologic studies) (15) is imperfect. One should be
especially careful when recommending conservative man-
agement of VF survivors with severely impaired left ventri-
cle. An EF 35% not only identifies VT/VF survivors for
whom ICD implantation offers the greatest advantage (in
terms of survival benefits) when no “treatable causes for the
arrhythmias” are apparent (16,17). Also, a low EF also
identifies patients for whom revascularization may not
suffice for preventing recurrent VT/VF (18,19) even when
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the original arrhythmia appeared to be due to ischemia (19).
As pointed out by the authors, patients with potentially
reversible causes of VT/VF need more aggressive evaluation
and treatment than is currently practiced. Indeed, more
research is needed to identify the truly reversible causes of
VT/VF and the optimal way to treat them.
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